期刊文献+

替米沙坦对早期高脂喂养OLETF大鼠代谢综合征相关因素的影响 被引量:2

Effect of Telmisartan on metabolic syndrome correlation factor of OLETF rats fed with high-fat diet
下载PDF
导出
摘要 目的观察替米沙坦对早期高脂喂养自发性2型糖尿病(T2DM)OLETF大鼠代谢综合征相关因素的影响。方法 OLETF大鼠48只,根据OGTT 2 h血糖和体重随机分为5组:替米沙坦组(L)、替米沙坦联合二甲双胍组(LM)、吡格列酮组(P)、二甲双胍组(M)和高脂对照组(O)。LETO大鼠12只,为非糖尿病对照组(NC)。22周龄对未发生T2DM大鼠实施药物干预。48周龄观察代谢综合征相关指标:T2DM发病率、FFA、血脂及体重变化。结果 L组糖尿病发病率与O组比较有下降趋势,但差异无显著性(P=0.085)。LM组糖尿病发病率与O组比较差异有显著性(P=0.035);FFA、TC、TG、LDL均低于O组,差异有显著性(P分别为0.040、0.023、0.037和0.000)。P组体重高于其他各组,差异有显著性(P<0.05)。结论替米沙坦联合二甲双胍能够降低高脂喂养OLETF大鼠T2DM发病率,并调节FFA及血脂水平且不增加OLETF大鼠体重,从而改善代谢综合征状况。 【Objective】 To investigate the effect of Telmisartan on metabolic syndrome correlation factor in OLETF rats fed with high-fat diet.【Methods】 According to OGTT 2 h and body weight,forty-eight OLETF rats were randomly divided into five groups: Telmisartan(group L),combination of Telmisartan and Metformin(group LM),Pioglitazone(group P),Metformin(group M) and high-fat diet(group O).Twelve LETO rats fed with normal diet served as normal control group(group NC).At forty-eight weeks,morbidity of diabetes,FFA,serum lipids and body weight were observed after twenty-two weeks treated drugs.【Results】 Compared with group O,T2DM was decreased but no statistical significance(P =0.085).T2DM in group LM was significantly lower than group O(P =0.035);Compared with group O,the FFA,TC,TG,LDL were markedly decreased(P =0.040,0.023,0.037 and 0.000,respectively).The body weight of group P was higher than that of rats in other groups(P 0.05).【Conclusion】 Combination of Telmisartan and Metformin can prevent the morbidity of diabetes of OLETF rats fed with high-fat diet and improve FFA,serum lipid disorders,and the body weight keep stable.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2011年第14期1577-1579,共3页 China Journal of Modern Medicine
关键词 替米沙坦 OLETF大鼠 代谢综合征 Telmisartan OLETF rat metabolic syndrome
  • 相关文献

参考文献12

  • 1LAKKA HM, LAAKSONEN DE, LAKKA TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men[J]. JAMA, 2002, 288(21): 2709-2716.
  • 2HANSON RL, IMPERATORE G, BENNETT PH, et al. Components of the metabolin syndrome and incidence of type 2 diabetes[J]. Diabetes, 2002, 51(10): 3120-3127.
  • 3KANEKO T, WANG PY, WANG Y, et al. The long-term effect of low-carbohydrate/high-fat diet on the development of diabetes mellitus in spontaneously diabetic rats [J]. Diabetes Metab, 2000, 26(6): 459-464.
  • 4ARAKI K, MASAKI T, KATSURAGI I, et al. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice [J]. Hypertension, 2006, 48(1): 51-57.
  • 5LEE MG, CHOI YH, LEE I. Effects of diabetes mellitus induced by alIoxan on the pharmacokinetics of metformin in rats: restoration of pharmacokinetic parameters to the control state by insulin treatment[J]. J Pharm Pharm Sci, 2008, 11(1): 88-103.
  • 6CHOI SH, ZHAO ZS, LEE YJ, et al. The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats [J]. Diabetes Metab Res Rev, 2007, 23(5): 411-418.
  • 7MORAN TH, BI S. Hyperphagia and obesity of OLETF rats lacking CCK1 receptors: developmental aspects[J']. Dev Psychobiol, 2006, 48(5): 360-367.
  • 8GRUNDY SM, BREWER HB JR, CLEEMAN JI, et al. Definition of metabolic syndrome; report of the national heart, lung, and blood Institute/American Heart Association Conference on scientific issues related to definition[J]. Circulation, 2004, 109(3): 433--438.
  • 9CERF ME. High fat programming of beta-cell failure[J]. Adv Exp Med Bid, 2010, 654: 77-89.
  • 10NAKAMURA T, KAWACHI K, SAITO Y, et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldostemne and adiponectin in hypertension[J]. Int Heart J, 2009, 50(4): 501-512.

同被引文献23

  • 1Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets[J]. Artefioseler Thromb Vasc Biol, 2012, 32(8): 1771-1776.
  • 2Ivczic-Lalic D, Bergman Markovic B, Kranjcevic K, et al. Diversity of metabolic syndrome criteria in association with cardiovascular diseases-a family medicine-based investigation[J]. Med Sci Monit, 2013, 19: 571-578.
  • 3Vyssoulis G, Karpanou E, Adamopoulos D, et al. Metabolic syndrome and atrial fibrillation in patients with essential hypertension[J]. Nutr Metab Cardiovase Dis, 2013, 23(2): 109-114.
  • 4Ji Q, Liu H, Mei Y, et al. Expression changes of ionic channels in early phase of cultured rat atrial myocytcs induced by rapid pacing[J]. Cardiothorac Surg, 2013, 29(8): 194.
  • 5Xu Y, Sharma D, Li G, et al. Atrial remodeling: new pathophysiological mechanism of atrial fibrillation[J]. Med Hypotheses, 2013, 80(1): 53-56.
  • 6Krogh-Madsen T, Abbott GW, Christini DJ. Effects of electrical and structural remodeling on atrial fibrillation maintenance: a simulation study[J]. PLoS Comput Biol, 2012, 8(2): e1002390.
  • 7Onuchina EL, Solov'ev OV, Mochalova OV, et al. Metabolic syndrome and chronic persistent atrial fibrillation[J]. Klin Med (Mosk), 2011, 89(1): 26-31.
  • 8Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study[J]. Circulation, 2008, 117(10): 1255-1260.
  • 9Vyssoulis G, Karoanou E, Adarnopoulos D, et al. Metabolic syndrome and atrial fibrillation in patients with essential hypertension[J]. Nutr Metal) Cardiovasc Dis, 2013, 23(2): 109-114.
  • 10Chen HY, Xu Z, Chen LF, et al. Valsartan and telmisartan abrogate angiotensin H-induced dowrtregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARy activation[J]. Cardiovasc Pharmacol, 2012, 59(6): 570-575.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部